Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|December 22, 2022

Determining Cisplatin Eligibility for Patients with MIBC

Author(s)Karim Chamie, MD

Dr Chamie explains how cisplatin eligibility is defined in patients with MIBC and how many patients in his practice receive neoadjuvant cisplatin therapy.

Episodes in this series

EP. 1 Case 1 Presentation: A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer (MIBC)

EP. 1 Case 1 Presentation: A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer (MIBC)

EP. 2 Determining Cisplatin Eligibility for Patients with MIBC

EP. 2 Determining Cisplatin Eligibility for Patients with MIBC

EP. 3 Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy

EP. 3 Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy

EP. 4 Communication and Follow-Up Strategies After Referring a Patient with MIBC to Medical Oncology

EP. 4 Communication and Follow-Up Strategies After Referring a Patient with MIBC to Medical Oncology

EP. 5 Case 2 Presentation: A 77-Year-Old Man With MIBC

EP. 5 Case 2 Presentation: A 77-Year-Old Man With MIBC

EP. 6 Unmet Needs and Clinical Challenges in the Management of MIBC

EP. 6 Unmet Needs and Clinical Challenges in the Management of MIBC

EP. 7 Potential Future Approaches to Neoadjuvant and Adjuvant Immunotherapy for MIBC

EP. 7 Potential Future Approaches to Neoadjuvant and Adjuvant Immunotherapy for MIBC

EP. 8 Clinical Pearls for Community Urologists Treating Patients with MIBC

EP. 8 Clinical Pearls for Community Urologists Treating Patients with MIBC

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Sarah Azari, MD, on early sexual health education for women with bladder cancer

BySarah Azari, MD

February 6th 2026

FDA premarket approval sought for Signatera CDx test in MIBC

ByHannah Clarke

February 2nd 2026

Kristen Scarpato, MD, on combination strategies in BCG-naïve NMIBC

ByKristen R. Scarpato, MD, MPH

January 31st 2026

John Sfakianos, MD, on dual immune checkpoint inhibition in NMIBC

ByJohn P. Sfakianos, MD

January 29th 2026

Pedro Freitas, MD, on consolidative surgery vs prolonged systemic therapy in MIBC

ByPedro F.S. Freitas, MD

January 26th 2026

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Trending on Urology Times

The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD

FDA approves sildenafil oral film for men with erectile dysfunction

Pearls & Perspectives: Modern Semen Testing and Male Fertility Care, with Thomas Masterson, MD

Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC

URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues